Cancer Letters, Год журнала: 2022, Номер 547, С. 215862 - 215862
Опубликована: Авг. 8, 2022
Язык: Английский
Molecular Biomedicine, Год журнала: 2021, Номер 2(1)
Опубликована: Июль 9, 2021
Cancer is one of the lethal diseases that arise due to molecular alterations in cell. One those associated with cancer corresponds differential expression Farnesoid X receptor (FXR), a nuclear regulating bile, cholesterol homeostasis, lipid, and glucose metabolism. FXR known regulate several diseases, including cardiovascular two highly reported causes mortality globally. Recent studies have shown association overexpression development progression different types cancers breast, lung, pancreas, oesophagus. It has also been tissue-specific cell-specific roles various cancers. modulate cell-signalling pathways such as EGFR/ERK, NF-κB, p38/MAPK, PI3K/AKT, Wnt/β-catenin, JAK/STAT along their targets caspases, MMPs, cyclins; tumour suppressor proteins like p53, C/EBPβ, p-Rb; cytokines; EMT markers; many more. Therefore, high potential novel biomarkers for diagnosis, prognosis, therapy cancer. Thus, present review focuses on diverse role its agonists antagonists.
Язык: Английский
Процитировано
46
Frontiers in Pharmacology, Год журнала: 2021, Номер 12
Опубликована: Апрель 22, 2021
Chemoresistance is one of the leading causes for failure tumor treatment. Hence, it necessary to study further and understand potential mechanisms resistance design develop novel anti-tumor drugs. Post-translational modifications are critical proteins’ function under physiological pathological conditions, among which ubiquitination most common one. The protein degradation process mediated by ubiquitin-proteasome system well-known modification. However, also participates in regulation many other biological processes, such as trafficking protein-protein interaction. A group proteins named deubiquitinases can hydrolyze isopeptide bond disassemble ubiquitin-protein conjugates, thus preventing substrate form or outcomes. Ubiquitin-specific protease 7 (USP7) extensively studied deubiquitinases. USP7 exhibits a high expression signature various malignant tumors, increased often indicates poor prognosis, suggesting that marker prognosis drug target therapy. In this review, we first discussed structure USP7. Further, summarized underlying cells therapies, provided theoretical support targeting overcome resistance, some inspiration development inhibitors.
Язык: Английский
Процитировано
42
Life Sciences, Год журнала: 2022, Номер 292, С. 120322 - 120322
Опубликована: Янв. 11, 2022
Язык: Английский
Процитировано
31
Frontiers in Oncology, Год журнала: 2022, Номер 12
Опубликована: Март 17, 2022
Bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extraterminal (BET) family, is considered to be major driver cancer cell growth new target for therapy. Over 30 targeted inhibitors currently in preclinical clinical trials have significant inhibitory effects on various tumors, including acute myelogenous leukemia (AML), diffuse large B lymphoma, prostate cancer, breast so on. However, resistance frequently occurs, revealing limitations BET inhibitor (BETi) therapy complexity BRD4 expression mechanism action pathway. Current studies believe that when internal external environmental conditions cells change, tumor can directly modify proteins by posttranslational modifications (PTMs) without changing original DNA sequence change their functions, epigenetic also activated form heritable phenotypes response stresses. In fact, research constantly being supplemented with regards regulatory role tumors closely related PTMs. At present, PTMs mainly include ubiquitination phosphorylation; former regulates stability mediates BETi resistance, while latter biological functions BRD4, such as transcriptional regulation, cofactor recruitment, chromatin binding same time, other PTMs, hydroxylation, acetylation methylation, play roles regulation. The diversity, reversibility affect structure, function participate occurrence development regulating tumor-related genes even become core undeniable mechanism. Therefore, targeting BRD4-related modification sites or enzymes may an effective strategy prevention treatment. This review summarizes different types, elucidates pathogenesis corresponding cancers, provides theoretical reference identifying targets combination strategies, discusses opportunities, barriers, PTM-based therapies future
Язык: Английский
Процитировано
30
Cancer Letters, Год журнала: 2022, Номер 547, С. 215862 - 215862
Опубликована: Авг. 8, 2022
Язык: Английский
Процитировано
28